glp-1 obesity drug news today october 23 2025 oct GLP-1 Drugs: 2025 Pulse Survey (U.S.) New Daily GLP-1 Weight Loss
Description
The country is well-positioned to become both a major producer and consumer of GLP-1 therapies
Future efforts should address affordability and accessibility through health economic analyses and policy-driven approaches
[DOI] [PMC free article] [PubMed] [Google Scholar] 87.Triplitt C, Chiquette E
If a recent evaluation was completed and appropriate follow-up scheduled, reexamination is not warranted
In August 2019, the company received the nod for Xultophy, a combo of insulin degludec and liraglutide
Individual response to GLP-1 medications varies
